Study on the efficacy of decitabine combined with CAG regimen in the treatment of refractory acute myeloid leukemia
Objective To investigate the efficacy of decitabine(DAC)combined with the CAG regimen in the treatment of refractory acute myeloid leukemia(RAML).Methods A total of 80 patients with RAML treated in our hospital from June 2020 to June 2023 were selected and randomly divided into a control group and an experimental group,with 40 cases in each group.The control group received the CAG regimen,while the experimental group was additionally treated with DAC.Clinical efficacy,immune cell markers before and after chemotherapy,platelet(PLT)and red blood cell transfusion volumes,increases in PLT and hemoglobin(HGB)levels,and the incidence of adverse reactions were compared between the two groups.Results After chemotherapy,the overall treatment efficacy and levels of CD3+,CD4+,and CD4+/CD8+in the experimental group were significantly higher than those in the control group,while the CD8+level was significantly lower than that in the control group.During supportive treatment after chemotherapy,the PLT and red blood cell transfusion volumes in the experimental group were significantly lower than those in the control group,and the increases in PLT and HGB levels were significantly higher than those in the control group.These differences between the groups were statistically significant(x2=5.115,t=5.043,6.632,2.354,5.528,4.798,5.012,21.174,17.528,all P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups during chemotherapy(x2=0.220,P＞0.05).Conclusion The DAC combined with the CAG chemotherapy regimen can improve the clinical efficacy in RAML patients,enhance immune function,inhibit tumor progression,promote bone marrow hematopoietic recovery,and is safe to use.
万方数据
维普
